Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.

MLA

Shitara, Kohei, et al. “Neoadjuvant and Adjuvant Pembrolizumab plus Chemotherapy in Locally Advanced Gastric or Gastro-Oesophageal Cancer (KEYNOTE-585): An Interim Analysis of the Multicentre, Double-Blind, Randomised Phase 3 Study.” The Lancet. Oncology, vol. 25, no. 2, Feb. 2024, pp. 212–24. EBSCOhost, https://doi.org/10.1016/S1470-2045(23)00541-7.

APA

Shitara, K., Rha, S. Y., Wyrwicz, L. S., Oshima, T., Karaseva, N., Osipov, M., Yasui, H., Yabusaki, H., Afanasyev, S., Park, Y.-K., Al-Batran, S.-E., Yoshikawa, T., Yanez, P., Dib Bartolomeo, M., Lonardi, S., Tabernero, J., Van Cutsem, E., Janjigian, Y. Y., Oh, D.-Y., … Bang, Y.-J. (2024). Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. The Lancet. Oncology, 25(2), 212–224. https://doi.org/10.1016/S1470-2045(23)00541-7

Chicago

Shitara, Kohei, Sun Young Rha, Lucjan S Wyrwicz, Takashi Oshima, Nina Karaseva, Mikhail Osipov, Hisateru Yasui, et al. 2024. “Neoadjuvant and Adjuvant Pembrolizumab plus Chemotherapy in Locally Advanced Gastric or Gastro-Oesophageal Cancer (KEYNOTE-585): An Interim Analysis of the Multicentre, Double-Blind, Randomised Phase 3 Study.” The Lancet. Oncology 25 (2): 212–24. doi:10.1016/S1470-2045(23)00541-7.